MedPath

Effects of Oncological Treatment During Pregnancy on Mother and Child

Recruiting
Conditions
Cancer
Pregnancy
Registration Number
NCT00330447
Lead Sponsor
University Hospital, Gasthuisberg
Brief Summary

The researchers aim to investigate the outcome (overall survival) of mothers who are diagnosed and/or treated for cancer during pregnancy. Furthermore they want to test the hypothesis that children who were exposed to cancer or cancer treatment (cytotoxic drugs, radiation therapy, targeted therapy,...) develop normally (neurologic and cardiologic examination).

Detailed Description

Study contains several study parts (protocol version 4.4):

\*\*\*\*\*\*\*\*\*\*Part I. Pregnancy, delivery and maternal health\*\*\*\*\*\*\*\*\*\* Part I.I.A. Registration study 'Cancer during pregnancy' mother and neonate None Part I.I.B. Effects of prenatal exposure to cancer treatment on fetal growth. The association between placental pathophysiologic mechanisms (histopathology and immunohistochemistry), circulating maternal factors and fetal growth.

From participating women, a maternal blood sample will be collected during or shortly after birth. Also, an umbilical cord blood sample and placental and umbilical cord biopsies will be drawn.

Part I.II. Measurement of maternal and paternal anxiety and emotional needs when confronted with a cancer diagnosis during pregnancy The participants will be asked to complete questionnaires.

\*\*\*\*\*\*\*\*\*\*Part II. Child\*\*\*\*\*\*\*\*\*\* Long term follow up of children and adolescents in utero exposed to chemotherapy and/or radiotherapy Regular check-ups of the child, at the age of 6 months, 18 months, 3y, 6y, 9y, 12y, 15y, and 18y, and after the age of 18 years: 5-yearly cardiologic assessment and questionnaires (23y, 28y, 33y, 38y, and 43y). Optional at the ages of 9y, 12y, 15y and 18y: MRI session.

Summary part I:

Prospectively the outcome of mothers diagnosed and/or treated for cancer during pregnancy will be registered and investigated.

Summary Part II:

In a prospective trial we invite children that were exposed to cytotoxic drugs or radiotherapy in utero for a standardized neurological and cardiological examination. The examinations will be done by qualified psychologists, neurological and cardiological pediatricians.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
5000
Inclusion Criteria
  • Children that were prenatally exposed to cancer of cancer treament. Informed Consent is asked from parents. From the age of 12 years, informed assent is additionally asked from the child. After the age of 18 years, informed consent is solely asked of the offspring.
Exclusion Criteria
  • Mentally disabled or significantly altered mental status that would prohibit the understanding and giving of informed consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Follow-up of the children antenatally exposed to chemotherapy or radiotherapyanticipated

neurologic and cardiologic outcome

Follow-up of the mothers diagnosed with cancer during pregnancyanticipated

treatment during pregnancy, obstetrical outcome, maternal survival

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (33)

UCL Brussels (2013-ongoing)

🇧🇪

Brussels, Belgium

Universitätsklinik Freiburg (retrospective until 2018)

🇩🇪

Freiburg, Germany

N.N.Blokchin National Medical Research Center of Oncology (2013-2018 retrospective; 2018-ongoing prospective)

🇷🇺

Moscow, Russian Federation

Instituto Alexander Fleming

🇦🇷

Buenos Aires, Argentina

Hellenic Anticancer-Oncological Hospital of Athens (retrospective 2015-2018)

🇬🇷

Athens, Greece

Ioannina University Hospital (retrosepctive 2015-2018)

🇬🇷

Ioánnina, Greece

CIttà della Salute e della Scienza di Torino (2015-ongoing)

🇮🇹

Torino, Italy

Regional Hospital of High Specialty of Ixtapaluca (2018-ongoing)

🇲🇽

Ixtapaluca, Mexico

Haukeland University Hospital (2017-ongoing)

🇳🇴

Bergen, Norway

University Hospital Krakow (2018-ongoing)

🇵🇱

Kraków, Poland

Universitätsklinik für Frauenheilkunde und Geburtshilfe (retrospective 2016-2018)

🇦🇹

Graz, Austria

Hippokration Hospital (retrospective 2015-2018)

🇬🇷

Thessaloníki, Greece

European Institute of Oncology (2010-ongoing)

🇮🇹

Milan, Italy

Erasmus Medical Center (2014-ongoing)

🇳🇱

Rotterdam, Netherlands

Medyczne Macierzynstwo (retrospective 2010-2018)

🇵🇱

Kraków, Poland

Pozanan University of Medical Sciences (2017-ongoing)

🇵🇱

Poznań, Poland

Almazov National Medical Research Center (2018-ongoing)

🇷🇺

Saint Petersburg, Russian Federation

F.Hached University Teaching Hospital (retrospective 2016-2018)

🇹🇳

Sousse, Tunisia

3rd medical faculty of Charles University (2010-ongoing)

🇨🇿

Prague, Czechia

Cooper University Hospital (2015-ongoing)

🇺🇸

Camden, New Jersey, United States

UZ Gasthuisberg, Katholieke Universiteit Leuven (2004-ongoing)

🇧🇪

Leuven, Belgium

University Hospital Ostrava (2018-ongoing)

🇨🇿

Ostrava, Czechia

Euroclinic Hospital (2016-ongoing)

🇬🇷

Athens, Greece

Fondazione IRCCS Ca'Granda Ospedale Maggiore (2012-ongoing)

🇮🇹

Milan, Italy

Copenhagen University Hospital (2015-ongoing)

🇩🇰

Copenhagen, Denmark

Hopital Bichat-Claude-Bernard (retrospective until 2018)

🇫🇷

Paris, France

Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico Milano (2017-ongoing)

🇮🇹

Milan, Italy

San Raffaele Hospital (2017-ongoing)

🇮🇹

Milan, Italy

Karolinska University Hospital (2017-ongoing)

🇸🇪

Stockholm, Sweden

Grigoriev Institute for medical Radiology (retrospective until 2018)

🇺🇦

Kharkov, Ukraine

Hospital de Vila Franca de Xira (2017-ongoing)

🇵🇹

Vila Franca De Xira, Portugal

Trakya University Faculty of Medicine (retrospective 2015-2018)

🇹🇷

Edirne, Turkey

Research Center for Obstetrics, Gynecology and Perinatology (2014-ongoing)

🇷🇺

Moscow, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath